Rebecca Roth1, Sebastian Dieng2, Alisa Oesterle2, Günter Feick3, Günther Carl4, Andreas Hinkel5, Thomas Steiner6, Björn Theodor Kaftan7, Frank Kunath8, Boris Hadaschik9, Simba-Joshua Oostdam10, Rein Jüri Palisaar11, Mateusz Koralewski12, Burkhard Beyer13, Björn Haben14, Igor Tsaur15, Simone Wesselmann16, Christoph Kowalski16. 1. Institute of Medical Statistics and Computational Biology (IMSB), Medical Faculty, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany. Rebecca.roth@uni-koeln.de. 2. OnkoZert, Gartenstraße 24, 89231, Neu-Ulm, Germany. 3. Federal Association of German Prostate Cancer Patient Support Groups, Thomas-Mann-Str. 40, 5311, Bonn, Germany. 4. Help for Prostate Cancer Patients (Förderverein Hilfe Bei Prostatakrebs e.V., FHbP), Louise Schroeder Ring 2, 25436, Tornesch, Germany. 5. Franziskus Hospital, Kiskerstraße 26, 33615, Bielefeld, Germany. 6. Helios Klinikum Erfurt, Nordhäuser Straße 74, 99089, Erfurt, Germany. 7. Städtisches Klinikum Lüneburg, Bögelstraße 1, 21339, Lüneburg, Germany. 8. Department of Urology and Pediatric Urology, University Hospital Erlangen, FAU Erlangen-Nürnberg, Krankenhausstraße 12, 91052, Erlangen, Germany. 9. Klinik und Poliklinik für Urologie, Kinderurologie und Uroonkologie, Universitätsklinikum Essen (AöR), Hufelandstraße 55, 45147, Essen, Germany. 10. Vinzenz-Krankenhaus Hannover, Lange-Feld-Str. 31, 30559, Hannover, Germany. 11. Urologische Klinik, Marien Hospital Herne, Universitätsklinikum der Ruhr-Universität Bochum, Mitten in der ST. ELISABETH GRUPPE GmbH, Katholische Kliniken Rhein-Ruhr, Widumer Str. 8, Herne, 44627, Germany. 12. Urologie, Krankenhaus der Barmherzigen Brüder Trier, Nordallee 1, 54292, Trier, Germany. 13. Martini-Klinik Prostate Cancer Center Hamburg, Martinistraße 52, 20246, Hamburg, Germany. 14. St. Marien Hospital Ahaus, Wüllener Str. 101, 48683, Ahaus, Germany. 15. Klinik und Poliklinik für Urologie und Kinderurologie, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Langenbeckstraße 1, 55131, Mainz, Germany. 16. German Cancer Society, Kuno-Fischer-Straße 8, 14057, Berlin, Germany.
Abstract
PURPOSE: The self-reported functional status (sr-FS) of prostate cancer (PCa) patients varies substantially between patients and health-care providers before treatment. Information about this issue is important for evaluating comparisons between health-care providers and to assist in treatment decision-making. There have been few reports on correlates of pretherapeutic sr-FS. The objective of the article, therefore, is to describe clinical and sociodemographic correlates of pretherapeutic sr-FS, based on a subset of the TrueNTH Global Registry, a prospective cohort study. METHODS: A total of 3094 PCa patients receiving local treatment in 44 PCa centers in Germany were recruited between July 2016 and April 2018. Multilevel regression models were applied to predict five pretherapeutic sr-FS (EPIC-26) scores based on clinical characteristics (standard set suggested by the International Consortium for Health Outcomes Measurement), sociodemographic characteristics, and center characteristics. RESULTS: Impaired pretherapeutic sr-FS tended to be associated with lower educational level and poorer disease characteristics-except for "urinary incontinence" which was only associated with age. Notably, age was a risk factor ("urinary incontinence," "urinary irritative/obstructive," "sexual") as well as a protective factor ("hormonal") for pretherapeutic sr-FS. Pretherapeutic sr-FS varies little across centers. CONCLUSIONS: Pretherapeutic sr-FS varies by clinical patient characteristics and age as well as by socioeconomic status. The findings point out the benefit of collecting and considering socioeconomic information in addition to clinical and demographic patient characteristics for treatment decision-making and fair comparisons between health-care providers.
PURPOSE: The self-reported functional status (sr-FS) of prostate cancer (PCa) patients varies substantially between patients and health-care providers before treatment. Information about this issue is important for evaluating comparisons between health-care providers and to assist in treatment decision-making. There have been few reports on correlates of pretherapeutic sr-FS. The objective of the article, therefore, is to describe clinical and sociodemographic correlates of pretherapeutic sr-FS, based on a subset of the TrueNTH Global Registry, a prospective cohort study. METHODS: A total of 3094 PCapatients receiving local treatment in 44 PCa centers in Germany were recruited between July 2016 and April 2018. Multilevel regression models were applied to predict five pretherapeutic sr-FS (EPIC-26) scores based on clinical characteristics (standard set suggested by the International Consortium for Health Outcomes Measurement), sociodemographic characteristics, and center characteristics. RESULTS: Impaired pretherapeutic sr-FS tended to be associated with lower educational level and poorer disease characteristics-except for "urinary incontinence" which was only associated with age. Notably, age was a risk factor ("urinary incontinence," "urinary irritative/obstructive," "sexual") as well as a protective factor ("hormonal") for pretherapeutic sr-FS. Pretherapeutic sr-FS varies little across centers. CONCLUSIONS: Pretherapeutic sr-FS varies by clinical patient characteristics and age as well as by socioeconomic status. The findings point out the benefit of collecting and considering socioeconomic information in addition to clinical and demographic patient characteristics for treatment decision-making and fair comparisons between health-care providers.
Authors: Melanie Calvert; Jane Blazeby; Douglas G Altman; Dennis A Revicki; David Moher; Michael D Brundage Journal: JAMA Date: 2013-02-27 Impact factor: 56.272
Authors: Steven M Lucas; Tae-Kyung Kim; Khurshid R Ghani; David C Miller; Susan Linsell; Jay Starr; James O Peabody; Patrick Hurley; James Montie; Michael L Cher Journal: Urology Date: 2017-06-23 Impact factor: 2.649
Authors: Anne Holck Storås; Martin G Sanda; Montse Ferrer; Jon Håvard Loge; Alv A Dahl; Eivind A S Steinsvik; Ferran Guedea; Milada Cvancarova; Sophie D Fosså Journal: Clin Genitourin Cancer Date: 2014-01-03 Impact factor: 2.872
Authors: Matthew J Resnick; Daniel A Barocas; Alicia K Morgans; Sharon E Phillips; Tatsuki Koyama; Peter C Albertsen; Matthew R Cooperberg; Michael Goodman; Sheldon Greenfield; Ann S Hamilton; Karen E Hoffman; Richard M Hoffman; Sherrie H Kaplan; Dan McCollum; Lisa E Paddock; Janet L Stanford; Antoinette M Stroup; Xiao-Cheng Wu; David F Penson Journal: Eur Urol Date: 2014-08-28 Impact factor: 20.096
Authors: Arthur Hartz; Tao He; Seth Strope; D Richard Cutler; Gerald Andriole; Christopher Dechet Journal: J Urol Date: 2012-10-31 Impact factor: 7.450
Authors: Ethan Basch; Allison M Deal; Mark G Kris; Howard I Scher; Clifford A Hudis; Paul Sabbatini; Lauren Rogak; Antonia V Bennett; Amylou C Dueck; Thomas M Atkinson; Joanne F Chou; Dorothy Dulko; Laura Sit; Allison Barz; Paul Novotny; Michael Fruscione; Jeff A Sloan; Deborah Schrag Journal: J Clin Oncol Date: 2015-12-07 Impact factor: 44.544
Authors: Bruce L Jacobs; Samia H Lopa; Jonathan G Yabes; Joel B Nelson; Amber E Barnato; Howard B Degenholtz Journal: Cancer Date: 2016-07-05 Impact factor: 6.860
Authors: M Klinkhammer-Schalke; M Koller; B Steinger; C Ehret; B Ernst; J C Wyatt; F Hofstädter; W Lorenz Journal: Br J Cancer Date: 2012-02-07 Impact factor: 7.640
Authors: Kendrick Koo; Nathan Papa; Melanie Evans; Michael Jefford; Maarten IJzerman; Victoria White; Sue M Evans; Eli Ristevski; Jon Emery; Jeremy Millar Journal: BMC Cancer Date: 2022-03-17 Impact factor: 4.430
Authors: Clara Breidenbach; Rebecca Roth; Lena Ansmann; Simone Wesselmann; Sebastian Dieng; Ernst-Günther Carl; Günter Feick; Alisa Oesterle; Peter Bach; Burkhard Beyer; Rainer Borowitz; Jörg Erdmann; Frank Kunath; Simba-Joshua Oostdam; Igor Tsaur; Friedemann Zengerling; Christoph Kowalski Journal: Cancer Med Date: 2020-03-31 Impact factor: 4.452